Tag: Ulrich Thienel
Phase 2 trial of RLS-0071 : ReAlta’s innovative approach to treating rare newborn disease
ReAlta Life Sciences, Inc., a clinical mid-stage biotech company focusing on rare life-threatening diseases, has announced the commencement of dosing in a Phase 2 clinical ... Read More